{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=27",
    "query": {
      "intervention": "Low Dose Drug A",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T18:46:07.932Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06075953",
      "title": "DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ductal Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrazole",
          "type": "DRUG"
        },
        {
          "name": "Testosterone + Anastrazole",
          "type": "DRUG"
        },
        {
          "name": "Elacestrant",
          "type": "DRUG"
        },
        {
          "name": "Z-endoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 400,
      "start_date": "2024-02-17",
      "completion_date": "2033-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 30,
      "location_summary": "Berkeley, California • Duarte, California • Irvine, California + 23 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06075953"
    },
    {
      "nct_id": "NCT04760691",
      "title": "Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV",
        "Prophylaxis",
        "Transgender"
      ],
      "interventions": [
        {
          "name": "Truvada alone",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Leuprolide 11.25mg intramuscular injection",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Estradiol 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Estradiol 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Estradiol 6 mg alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2021-03-01",
      "completion_date": "2025-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04760691"
    },
    {
      "nct_id": "NCT05143840",
      "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia, Chronic Phase",
        "Adult CML",
        "Leukemia, Myeloid",
        "Leukemia,Myeloid, Chronic"
      ],
      "interventions": [
        {
          "name": "Single Agent Asciminib",
          "type": "DRUG"
        },
        {
          "name": "Low TKI",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Elective Free Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2022-04-22",
      "completion_date": "2032-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05143840"
    },
    {
      "nct_id": "NCT01760889",
      "title": "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SPD489 low dose range (40mg, 80mg, and 100mg)",
          "type": "DRUG"
        },
        {
          "name": "SPD489 high dose range (120mg, 140mg and 160mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2013-02-01",
      "completion_date": "2013-04-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 4,
      "location_summary": "Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more",
      "locations": [
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "O'Fallon",
          "state": "Missouri"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760889"
    },
    {
      "nct_id": "NCT02488408",
      "title": "A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Bemcentinib",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BerGenBio ASA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2014-10-22",
      "completion_date": "2022-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Houston, Texas",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02488408"
    },
    {
      "nct_id": "NCT04005924",
      "title": "Effect of an Arabinogalactan Product",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postprandial Blood Glucose"
      ],
      "interventions": [
        {
          "name": "arabinogalactan",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Biofortis, Merieux NutriSciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-05-06",
      "completion_date": "2019-10-08",
      "has_results": false,
      "last_update_posted_date": "2021-07-21",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 1,
      "location_summary": "Addison, Illinois",
      "locations": [
        {
          "city": "Addison",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04005924"
    },
    {
      "nct_id": "NCT04361708",
      "title": "Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-05-08",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04361708"
    },
    {
      "nct_id": "NCT06601218",
      "title": "Impact of Daily Oral Cannabis Doses in Patients With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Cancers, Pain"
      ],
      "interventions": [
        {
          "name": "Oral cannabis low THC",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        },
        {
          "name": "Oral cannabis high THC",
          "type": "DRUG"
        },
        {
          "name": "Oral cannabis THC/CBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanna Babalonis, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-06-17",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06601218"
    },
    {
      "nct_id": "NCT06054464",
      "title": "A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PC14586",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PMV Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2023-09-19",
      "completion_date": "2024-02-06",
      "has_results": false,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06054464"
    },
    {
      "nct_id": "NCT02553265",
      "title": "Carbidopa for the Treatment of Excessive Blood Pressure Variability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dysautonomia, Familial",
        "Baroreflex Failure Syndrome"
      ],
      "interventions": [
        {
          "name": "Carbidopa Low-Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Carbidopa High-Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "10 Years to 60 Years"
      },
      "enrollment_count": 22,
      "start_date": "2015-09",
      "completion_date": "2019-05-10",
      "has_results": true,
      "last_update_posted_date": "2022-02-09",
      "last_synced_at": "2026-11-15T18:46:07.932Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02553265"
    }
  ]
}